Injectable semaglutide trials show similar percentage reductions, with some studies reporting 1015% weight loss at higher doses
In the UAE, peptide therapy must be prescribed and administered through a licensed medical clinic
Using Wegovy or its alternatives through Klinic increases the likelihood of insurance coverage since these drugs are FDA-approved specifically for weight loss
Semaglutide's long half-life of approximately 7 days (Kapitza et al., J Clin Pharmacol, 2015) means even a microdose lingers, so this approach is not risk-free, but the absolute exposure is low
Consistent with these mechanisms, adipocytes from individuals with IR and/or obesity exhibit reduced expression of key insulin signalling components, GLUT4 and IRS1, as well as impaired insulin-stimulated PI3K/Akt signalling [20] and decreased expression of key adipogenic transcription factors [21]